Glucos Viaflo Baxter

Glucos Viaflo Baxter is an intravenous (IV) solution containing glucose as the sole active ingredient. Marketed in the European Union, the product is supplied as a sterile liquid preparation for parenteral administration. While the specific concentration is not disclosed, the formulation is intended to deliver a source of carbohydrate energy directly into the bloodstream. It is classified as an excipient rather than a therapeutic drug.

Glucos Viaflo Baxter is used primarily as an intravenous source of glucose in clinical settings where rapid carbohydrate supplementation is required.

- To provide energy during perioperative fasting - To treat hypoglycemia when oral intake is not possible - As a carrier solution for compatible intravenous medications - To support patients receiving parenteral nutrition - To maintain blood glucose levels during critical care

Adverse reactions to Glucos Viaflo Baxter are generally related to the intravenous administration of glucose and the solution’s excipients.

Common: - Local irritation at the infusion site - Mild hyperglycemia - Nausea - Headache

Serious: - Severe hyperglycemia - Anaphylactic reaction - Electrolyte imbalance (e.g., hyponatremia) - Volume overload

When using Glucos Viaflo Baxter, clinicians should observe several precautionary measures to ensure patient safety and appropriate therapeutic outcomes.

- Assess baseline blood glucose before infusion - Adjust infusion rate in patients with diabetes or impaired glucose tolerance - Monitor for signs of fluid overload in patients with cardiac or renal dysfunction - Avoid use in patients with known hypersensitivity to the formulation components - Consider electrolyte status, especially sodium and potassium levels - Use aseptic technique to prevent contamination

Glucose solutions can interact with other intravenous agents or medical conditions, requiring careful management.

Avoid: - Concurrent administration with high‑dose insulin without monitoring - Co‑infusion with potassium chloride in patients at risk of hyperkalemia

Use with caution: - Simultaneous infusion with other hypertonic solutions (e.g., mannitol) - Patients receiving diuretics or fluid‑restrictive therapy - Use in patients with severe liver disease affecting glucose metabolism